Morgan Stanley Ups Rating on Biovail

Cites the company's deal with Johnson & Johnson ()'s Ortho-McNeil unit to market and distribute in the U.S. and Puerto Rico

Morgan Stanley raised its investment recommendation on Biovail (BVF ) to overweight from equal-weight.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.